Post Profile






First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.
read more

share

Related Posts


Adding Drug to Standard Chemotherapy Provides No Survival Benefit for Older Lung Cancer Patients

Health : Newswise Medical News

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over th...

Merck KGaA: Survival In 1st-Line Non-Small Cell Lung Cancer (NSCLC) Significantly Prolonged By Erbitux(R)

Health : Medical News Today

Data presented today at the 1st International Thoracic Oncology Congress Dresden (ITOCD) demonstrate that the addition of Erbitux® (cetuximab) to standard platinum-based chemotherapy in the 1st-line treatment of advanced NSCLC resul...

Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.

Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.

Comments


Copyright © 2016 Regator, LLC